However, in the study mentioned above by Kim et al., the authors observed that AIM2 mRNA and protein increased until seven days post-stroke with an AIM2 immuno-reactivity primarily co-localized in microglial (Iba-1) and endothelial cells (CD31). The gene discussed is PECAM1; the disease is stroke disorder.